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ABSTRACT  
Aims:  PPARα agonists are in current clinical use as hypolipidaemic agents and show 
significant antineoplastic effects in human glioblastoma models.  To date however, the 
expression of PPARα in large-scale glioblastoma data sets has not been examined.  We 
aimed to investigate the expression of the transcription factor PPARα in primary 
glioblastoma, the relationship between PPARα expression and patients’ clinicopathological 
features and other molecular markers associated with gliomagenesis. 
Methods and Results:  Using protein immuno-blotting techniques and RT-qPCR, PPARα 
was found to be significantly overexpressed in glioblastoma compared to control brain 
tissue (p=0.032 and p=0.005).  PPARA gene expression was found to be enriched in the 
classical glioblastoma subtype within The Cancer Genome Atlas (TCGA) data set.  
Although not associated with overall survival when assessed by immunohistochemistry, 
cross-validation with the TCGA data set and multivariate analyses identified PPARA gene 
expression as an independent prognostic marker for overall survival (p=0.042).  Finally, 
hierarchical clustering revealed novel, significant associations between high PPARA 
expression and a putative set of glioblastoma molecular mediators including EMX2, AQP4 
and NTRK2. 
Conclusions:  PPARα protein is overexpressed in primary glioblastoma and high PPARA 
gene expression functions as an independent prognostic marker in the glioblastoma TCGA 
data set.  Further studies are required to explore genetic associations with high PPARA 
expression and to analyse the predictive role of PPARα expression in glioblastoma models 
in response to PPARα agonists. 
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INTRODUCTION 
 
Primary glioblastoma has an incidence of 4/100,000 per year and a 3% five year overall 
survival rate.1  Glioblastoma is a molecularly heterogeneous cancer 2,3 and it is key that new 
tools are developed that better delineate its biological variants.4,5 
The peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription 
factors governing lipid, carbohydrate and amino-acid metabolism.6  Synthetic PPARα 
agonists such as fenofibrate and clofibrate are widely used clinically as hypolipidaemic 
agents.  A large study has suggested that the use of fibrates is associated with a reduced 
probability of death from cancer.7 
 
Fenofibrate and clofibrate have been reported to exert anticancer effects in breast cancer 
models,8,9 PPARα activation inhibits the growth of non-small cell lung carcinoma cells 10,11 
and suppresses tumour growth in ovarian carcinoma models.12  Conversely, 
overexpression of PPARα has been reported to predict reduced clinical survival in ovarian 
carcinoma cohorts .13 
 
The role of PPARα in pre-clinical models of high grade glial tumours is not yet fully 
elucidated.  However, fenofibrate exerts tumour suppressive effects via modulation of 
angiogenesis in a U87 mouse model of high grade glioma (HGG).14  Fenofibrate decreases 
the motility of HGG cells in vitro,15 induces G0/G1 cell cycle arrest and reduces HGG cell 
viability,16 decreases  expression of the glioma stem cell marker CD133 17 and induces 
BIM-mediated apoptosis.18  Most recently, fenofibrate has been shown to induce 
ketogenesis19 and inhibit glycolysis 20,21 in glioblastoma in vitro models.   
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PPARα is overexpressed in HGG in vitro compared to normal human astrocytes 15 and the 
expression of PPARα correlates with grade of malignancy in glial tumours.22  An 
association between hypoxic in vitro conditions and increased PPARα expression has been 
reported.23  However, to date PPARα expression has not been examined in large-scale 
glioblastoma cohorts nor its association between key clinicopathological covariates or 
genetic mediators determined. 
 
In this study we examined the expression of PPARα protein and PPARA mRNA in IDH1 
(isocitrate dehydrogenase)-wildtype primary human glioblastomas.  Wildtype IDH1 status is 
a key genetic marker in primary glioblastoma.24,25  We also investigated the relationship 
between PPARα expression and other clinicopathological factors.  Finally we used large 
scale microarray data to establish previously unreported genetic associations with high 
PPARA expression across the whole transcriptome.  
 
MATERIALS AND METHODS 
Study samples 
 
IDH1-wildtype glioblastoma surgical specimens (snap frozen), diagnosed 2010-2013, were 
obtained from the Brain Tumour Bank Southwest UK. Formalin-fixed paraffin-embedded 
(FFPE) tissue and clinical data were available for each patient.  FFPE tissue from 
histologically normal anterior temporal lobe resections and frozen post-mortem healthy 
cortical samples were used as controls.  BrainUK ethical approval (14/008, 15/017) and in 
collaboration with the UK Multiple Sclerosis Tissue Bank.   
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Protein extraction 
 
Protein was extracted from tissue samples using the Ambion® PARIS™ system (Life 
Technologies, UK).  Protein concentrations were determined using the Qubit® Quant-It 
protein kit and Qubit® Fluorometer (Thermofisher Scientific, UK).  
 
Western Blotting and immuno dot-blotting 
 
Both western blotting and immune dot blotting were carried out as previously described.26  
Primary antibodies were PPARα (1:2000 Abcam-ab8934) and GAPDH (1:10,000 Abcam-
ab9484).  Secondary anti-rabbit/anti-mouse horseradish peroxidise-conjugated antibodies 
(Abcam) were used to detect immunoreactivity.  Protein expression was visualised using 
chemiluminescence (Amersham ECL™) with the Biorad Universal III Bioplex Imager 
(Biorad, UK).  Densitometric analysis of protein dots was performed using ImageLab 
software (Biorad).    
 
FFPE RNA extraction and RT-qPCR 
 
Total RNA was extracted from either whole control tissue (n=17; x10 5µm FFPE unstained 
sections) or macro-dissected regions of glioblastoma (n=48; x10 5µm FFPE unstained 
sections) using the Omega EZNA.FFPE RNA spin column kit (OmegaBio-Tek, USA)  
including a gDNA elimination step.  RNA purity and quantification was determined using a 
Nanodrop1000.  RNA was reverse transcribed to cDNA using the Clontech 
TaKaRa PrimeScript 1st strand cDNA Synthesis Kit (Takara Bio, USA).   Real time 
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quantitative PCR was performed using a Step One Plus instrument with Taqman® Fast 
Gene Expression Mastermix (both Applied Biosytems) and assay on demand (AoD) gene 
expression products for PPARA (Hs00947536_m1) (amplicon length 62bp) and GAPDH 27 
(Hs02758991_g1) (amplicon length 93bp) (Taqman® MGB probes, FAM dye-labelled, 
Applied Biosytems).  The efficiency and linear range for both AoD were determined using a 
dilution series standard curve prior to expression analysis of the cohort.28  Relative gene 
expression was calculated using the 2-ΔΔCt method.29      
 
MGMT promoter methylation status and IDH1 R132H mutation analysis 
 
As part of the standard diagnostic assessment, MGMT promoter methylation was 
determined by methylation sensitive PCR 30 and IDH1R132H immunohistochemistry was 
performed.31 
 
Automated Immunohistochemistry (IHC) 
 
All stages of immunohistochemistry were performed using the Leica Bond autostaining 
platform and a Bond Polymer Refine Detection kit (Leica, IL, USA) as previously described 
.32  2µm sections were incubated with Bond epitope retrieval solution 1 (pH 6.0, 30 minutes) 
and PPARα antibody (1:55 Abcam-ab8934) followed by the standard autostainer 
procedures.  Sections from PPARα high/low expressing tumours established using 
immunoblotting were used as positive/negative controls for IHC antibody work up.  Primary 
antibody omission controls were included in each IHC run.  17 control and 100 glioblastoma 
samples were stained for PPARα. 
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The immunohistochemical expression of PPARα was quantified using a double-blind 
system (Table 1).  Addition of the intensity and extensivity scores gave a composite score.  
A score of ≥5 was considered high PPARα expression.  Assessments were conducted 
independently by researchers blinded to the clinical data (H.R.H and K.M.K).  Discrepant 
evaluations between researchers (difference in composite score ≥3 or difference in high vs 
low outcome score) triggered a consensus meeting and final expression score agreement.   
 
TCGA data set gene expression analysis 
 
The data was pre-processed using lowness normalisation, log-transformed and the mean 
used to calculate gene level summaries.33  The data was accessed and processed via the 
GlioVis online platform (http://gliovis.bioinfo.cnio.es). Differential expression analysis was 
performed using eBayes and lmFit functions of the 'limma' package with a log2 fold change 
of 1 and p-value of 0.05.34  Pearson correlation analysis was applied to significantly 
differentially expressed genes.  Cross-validation with the Rembrandt glioblastoma data set 
35 was carried out.  Gene nomenclature was cross-referenced against the NCBI database 
(https://www.ncbi.nlm.nih.gov/gene/) and all gene aliases were used in subsequent 
literature review. 
 
Statistical Analysis 
 
Mann-Whitney test was used to compare control vs disease protein/mRNA expression.  
Fisher's exact test was used to test possible associations between PPARα expression and 
clinicopathological covariates.  Overall survival (OS) was defined as the interval between 
the date of diagnosis and the date of death.  Kaplan-Meier survival curves were compared 
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with the log-rank test. Hazard ratios and 95% confidence intervals were calculated by 
univariate and multivariate Cox proportional hazards regression.  All statistical tests were 
two-tailed.  Differences at p<0.05 were considered significant.  Statistical tests carried out 
using GraphPad v5 (GraphPad, USA), IBM SPSS Statistics22 software (IBM, USA) and the 
GlioVis tool (http://gliovis.bioinfo.cnio.es).   
 
 
RESULTS 
PPARα protein and PPARA gene expression is increased in IDH1-wildtype 
glioblastoma  
 
The primary antibodies used throughout this study were validated for antibody specificity 
using western blotting (Figure 1A).  There was a significant increase in PPARα protein 
expression in the glioblastoma samples (p=0.032) (Figure 1B).  RT-qPCR showed a 2.03 
fold increase in PPARA mRNA expression in the glioblastoma samples compared to 
controls (p=0.005) (Figure 2). 
 
PPARA gene expression is differentially enriched in transcriptomic glioblastoma 
subtypes 
 
PPARA transcript expression is significantly increased in the classical glioblastoma subtype 
in both the TCGA (p=0.001) (Figure 3A) and Rembrandt (p=0.05) (Figure 3B) data sets 
when compared to proneural subtype.  Significantly decreased expression is noted in the 
mesenchymal subtype within the Rembrandt data set (p=0.002) (Figure 3B), an effect not 
found in the TCGA data. 
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Characterisation of PPARα IHC expression 
 
The control tissue showed neuronal PPARα cytoplasmic and variable nuclear positivity in 
cortical grey matter (Figure 4 A&B).  A negative white matter immunophenotype was seen.  
Where the scoring criteria established a high expression, a nuclear or mixed cytoplasmic 
and nuclear immunohistochemical expression pattern was seen (Figure 4 E&F).  In high 
expressing tumours, PPARα intratumoral heterogeneity was observed as admixed negative 
cells (Figure 4E).   
 
Associations between PPARα IHC score and clinicopathological variables 
 
The clinicopathological features of the glioblastoma cohort (n=100) are summarized in 
Table 2.  The mean age at diagnosis was 61years.  PPARα IHC scores were high in 60 and 
low in 40 glioblastoma samples. There was no significant association between PPARα IHC 
score and patient sex, patient age, Karnofsky Performance Score (KPS), tumour location 
and MGMT promoter methylation status (p>0.05 for all covariates) (Table 2).   
 
Association between PPARα IHC score and OS 
 
Univariate Cox’s proportional hazards analysis revealed no prognostic role for patient sex, 
age, KPS or MGMT promoter methylation status (Table 3).  A significantly reduced OS was 
seen for those with diffuse/multifocal/thalamic glioblastoma (median OS: 4 months).  OS 
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was significantly associated with surgical resection and adjuvant treatment.  In this cohort, 
there was no prognostic role for PPARα expression by IHC. 
 
Associations between TCGA PPARA gene expression and clinicopathological 
variables 
 
The clinicopathological features of the TCGA glioblastoma cohort (n=473) are summarized 
in Table 4.  The mean age at diagnosis was 59.7years.  There was no significant 
association between PPARA gene expression and patient age or MGMT promoter 
methylation status (p>0.05) (Table 4).   
 
PPARA gene expression is associated with OS in the TCGA dataset 
 
Univariate Cox’s proportional hazards analysis for OS revealed a significant prognostic role 
for age, MGMT methylation and adjuvant treatment (Table 5).  In this cohort, patients with 
high PPARA gene expression had a statistically significant increase in OS (upper quartile 
vs other 3 quartiles, median OS: 15.1 vs 13.6 months; log-rank p value=0.016) (Figure 5A). 
Analysis of classical glioblastoma only (as a model of almost exclusively IDH1-wildtype 
glioblastoma) additionally showed a significant increase in OS (upper quartile vs other 3 
quartiles, median OS: 16.6 vs 14.0 months; log-rank p value=0.006) (Figure 5B).   
 
PPARA gene expression is an independent prognostic biomarker 
 
168 missing values for MGMT status were observed in the TCGA data (Tables 4 & 5).  We 
found that missing MGMT values were significantly associated with OS and PPARA 
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expression (p<0.001; both).  In order to accommodate these missing data, multiple 
imputation was performed for missing MGMT values before multivariate analysis.  When a 
single extreme outlier in the TCGA data was excluded (OS = 127.6 months), this 
multivariate model indicated that the prognostic value of PPARA expression was 
independent of age, MGMT methylation status and adjuvant treatment (p=0.042) (Table 6). 
 
PPARA gene expression has significant genetic correlations in the TCGA dataset 
 
The TCGA dataset was interrogated to determine genetic associations with the 
prognostically significant high PPARA expression. Differential gene expression analysis 
revealed gene subsets clustering with high (n=39) and low (n=31) PPARA expression 
(Figure 6).  Of the gene expression values clustered with high PPARA expression, 10 have 
previously been associated with primary glioblastoma in published studies.  Each of these 
10 genes was significantly positively correlated with PPARA when analysed across all 
samples in the TCGA data set (n=489).  Of this group, 5 transcripts remained correlated 
when cross-referenced against the Rembrandt data set  (n=217) 35 (Table 7, Figure 7).    
 
 
DISCUSSION 
 
In this study we examined the expression of PPARα in IDH-wildtype glioblastoma,36 defined 
clinically as primary glioblastoma.37  PPARα agonists may have considerable advantages 
as repurposed antineoplastic agents for glioblastoma including good tolerance in chronic 
administration and a low side effect profile.  Indeed, fenofibrate intracranial drug delivery 
methods are currently in development.38 
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Our results indicate that the expression of PPARα protein and PPARA mRNA is 
significantly increased in glioblastoma. Whether this overexpression is an early or initiating 
event in the malignant transformation of glioma stem cells,39,40 is essential for on-going 
tumour progression or contributes to adjuvant therapy response,41 remains to be elucidated.   
 
We also report a pattern of mixed cytoplasmic and nuclear PPARα expression by IHC in the 
glioblastoma tissue.  Such a mixed pattern of protein localisation is consistent with the 
ligand activated transcription factor function of PPARα and has previously been reported in 
vitro.15 
 
In the present study, significant associations between OS and patient age, tumour location, 
MGMT methylation, extent of surgical resection and adjuvant treatment were seen.  This is 
consistent with published data.42,43  We also reported that PPARα expression by IHC 
showed no prognostic significance, although the sample size was limited.  However, post 
hoc interrogation of the TCGA data set showed high expression of PPARA was 
independently prognostically significant.  This model utilised a multiple imputation approach 
for missing MGMT values to avoid statistical bias which may be caused by excluding 
missing data.44  This model also excluded a single outlier.  No root cause could be found for 
this outlier as an inconsistent observation and we provided multivariate models with and 
without its inclusion.45  It is of note that this outlying OS value may reduce the power of 
future TCGA analyses.  Further work is needed examining the OS advantage of PPARα by 
IHC in a larger (prospectively collated) clinical cohort and whether PPARα may have 
translational relevance as a prognostic marker in diagnostic practice.     
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We have demonstrated enrichment for PPARA expression in classical glioblastoma, 
compared to proneural subtypes in both the TCGA and Rembrandt data sets.  Secondary 
IDH-mutant glioblastoma cluster in the proneural subtype and show a unique epigenetic 
phenotype of global DNA hypermethylation.46,47  Primary glioblastoma, lacking TP53 and 
IDH1/2 mutations are defined as having a classical gene signature 33,48 and are of interest 
in this study. The increased expression of PPARA in classical vs mesenchymal 
glioblastoma, seen in the Rembrandt data set alone, suggests that recurrent tumours, with 
a mesenchymal type gene signature,49,50 have decreased levels of this transcript.  Studies 
examining the genetic mechanisms mediating increased expression, demonstrated herein, 
as well as post treatment (recurrent tumour) expression are warranted. 
 
Although PPARα signalling has been associated with a variety of malignancies, the precise 
role of neoplastic PPARα expression remains to be elucidated.  In this study we used 
differential gene expression analysis to determine that 5 genes previously associated with 
gliomagenesis are correlated with high PPARA.  Of particular interest is the correlation 
between high PPARA and EGFR.  Glioblastomas with EGFR amplification or 
overexpression cluster in the classical expression subtype.33,51  It has recently been shown 
that PPARα enhances the transcription of EGFR.52  However, the prognostic significance of 
EGFR overexpression in glioblastoma is uncertain.53–55  Pre-clinical investigation of the 
antineoplastic effects of combined PPARα agonism and EGFR kinase inhibitors would be a 
logical extension to this study.  
 
EMX2, a transcription factor with key neurodevelopmental roles,56 reported here as 
correlating with high PPARA expression, may function as a tumour suppressor in 
glioblastoma models.57  The transcription factor NPAS3 has similarly been implicated in 
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neurodevelopment 58,59 and its knockdown induces aggressive anaplastic astrocytomas in 
xenograft models.60  Demonstrated herein, NPAS3 expression additionally correlates with 
PPARA, although its function in primary glioblastoma has not, to date, been reported.  Also 
significantly correlated by expression was the kinase NTRK2 which has been shown to 
correlate with improved glioma survival.61  Conversely, AQP4 has been associated with 
anti-apoptotic 62 and pro-invasive effects.63  Further work is required to determine the role of 
each of these molecular markers in the high PPARA expressing subgroup with improved 
OS that we have described.   
 
In summary, our study showed that PPARα is significantly overexpressed in primary 
glioblastoma.  Interrogation of the TCGA data set has revealed an independent prognostic 
role for PPARA expression and significant correlation with a set of glioblastoma-associated 
regulators.  Additional studies are required to determine whether a PPARα protein or gene 
expression signature has predictive value for PPARα agonists used as a novel therapy for 
patients with glioblastoma.    
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Figure 1:  PPARα protein expression in control and glioblastoma tissues.   (a) 
Western blot validation of antibodies used in immunoblotting experiments and 
immunohistochemistry.  (b) PPARα protein expression was examined in post-
mortem GM and WM control tissue samples (n=4 GM; n=4 WM) and glioblastoma 
(IDH1-wildtype) patient samples (n=28).  The test statistic is Mann Whitney test; 2 
tailed p value.  Error bars show standard error of the mean. *p<0.05. GAPDH, 
glyceraldehyde 3-phosphate dehydrogenase; GM, grey matter; WM, white matter.   
 
   
Figure 2: PPARA expression by RT-qPCR.  PPARA mRNA expression was 
examined in FFPE samples of control (histologically normal) cortex (n=17) and 
glioblastoma (IDH1-wildtype) (n=48) by RT-qPCR.  The geometric mean and 95% 
confidence interval are shown on a logarithmic scale (to base2).  The test statistic is 
Mann Whitney test; 2 tailed p value.  **p<0.01; GAPDH, glyceraldehyde 3-
phosphate dehydrogenase.  
 
Figure 3:  PPARA expression in transcriptome data sets.  (a) TCGA data set 
analysis (classical n=182 [37.2%], mesenchymal n=156 [31.9%], proneural n=151 
[30.9%]). (b)  Rembrandt data set analysis (classical n=79 [36.1%], mesenchymal 
n=70 [31.9%], proneural n=70 [31.9%]).  In the box plots the upper and lower 
“hinges” correspond to the 25th and 75th percentiles. The upper/lower whisker 
extends to the highest/lowest value that is within 1.5 * IQR (inter-quartile range). 
Data beyond the end of the whiskers are outliers. The test statistic is Tukey's honest 
significant differences.  Normalised and log transformed mRNA gene level 
summaries shown.  **p<0.01; *p<0.05; ns, not significant. IDH1 mutation status not 
available for the Rembrandt data set.  Data analysis carried out using GlioVis online 
tool. 
 
Figure 4:  Representative PPARα expression by IHC.  (a) and (b) control tissue 
showed cytoplasmic and some nuclear positivity in pyramidal neurones within the 
grey matter.  (c) and (d) low expression of PPARα in glioblastomas samples ranged 
from no expression (c) to some weak, predominately cytoplasmic expression (d).  (e) 
and (f) high expression of PPARα.  Negative staining regions in (f) represent 
microvascular proliferations. GM, grey matter.  Scale bar = 100µm. 
 
Figure 5:  Survival analysis for glioblastoma patients. Total TCGA data set 
analysed. (a) Kaplan-Meier plot of overall survival from TCGA data set - PPARA 
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expression vs survival: across all glioblastoma subtypes. (b) Kaplan-Meier plot of 
overall survival from TCGA data set - PPARA expression vs survival: restricted to 
classical glioblastoma subtypes.  Normalised and log transformed mRNA gene level 
summaries shown.  **p<0.01; *p<0.05.  HR; hazard ratio (95% CI).  Data analysis 
carried out using GlioVis online tool. 
 
 
Figure 6:  Hierarchical clustering analysis.  A heatmap displaying 70 differentially 
expressed genes.  Up-regulated genes (at least a 2-fold increase in gene 
expression) have positive values and are displayed red.  The lower yellow bar 
represents the low PPARA expressing samples, the blue bar the high PPARA 
expressing samples.  Columns represent the patient samples.  Rows represent 
individual differentially expressed genes. The spread of IDH1 mutations and MGMT 
promoter methylation status can be seen in the upper coloured bars.   
 
Figure 7: Analysis of PPARA-correlated genes. Genes previously associated with 
gliomagenesis and revealed by hierarchical clustering to be differentially expressed 
with high PPARA were examined by Pearson correlation analysis in paired samples 
in the TCGA microarray data set (n=489) and cross-validated with the Rembrandt 
microarray data set (n=217).  Results from correlations within the TCGA data set are 
shown.  All correlations are p<0.001 and Pearson r values are expressed for each 
correlation.  The 95% confidence interval is represented by the grey shaded area in 
each plot. The test statistic is Pearson's product moment correlation.  
 
  
HR Haynes et al 2016 
 
17 
 
Intensity Score Percentage Section Score 
NO STAIN 0 NO STAIN 0 
FAINT 1 1-25% 1 
MODERATE 2 26-50% 2 
STONG 3 51-75% 3 
  76-100% 4 
 
Table 1: IHC scoring system for PPARα expression. 
For both scores, any surrounding histologically normal cortex or necrotic regions were excluded 
from analysis.   
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Clinicopathological variable Patients 
(n=100) 
PPARα high PPARα low p-value 
Sex    0.828 
Male 68 40 28  
Female 32 20 12  
Age (years)    0.224 
<61 52 28 24  
≥61 48 32 16  
KPS *    0.061 
≥80 65 42 23  
<80 18 7 11  
Tumour Location **    0.474 
Frontal 25 13 12  
Non-frontal/diffuse/multifocal 67 42 25  
MGMT promoter methylation ***    0.543 
Methylated 49 26 23  
Unmethylated 49 32 17  
 
Table 2:  Association between PPARα expression by IHC and clinicopathological features of 
IDH1-wildtype glioblastoma. 
 
The test statistic is Fisher’s exact test; 2 tailed p value.  No significant associations as reported.      
KPS, Karnofsky Performance Score 
 
* 17 missing data points 
** 8 missing data points 
*** 2 missing data points 
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Factor n 
(events) 
Median OS  
(months) 
[95% CI] 
p-value 
(log rank) 
Hazard Ratio 
[95% CI] 
Sex 
   Male 
   Female 
 
68 (53) 
32 (34) 
 
12.0  [10.64, 13.36] 
10.0  [4.04, 15.96] 
 
0.149 
 
 
1 
1.36 [0.88, 2.09] 
Age 
   28 – 55 
   56 – 65 
   66 – 83  
 
32 (29) 
32 (27) 
36 (31) 
 
13.0  [10.74, 15.27] 
11.0  [7.67, 14.33] 
11.0  [7.08, 14.92] 
0.233  
1 
1.43 [0.85, 2.42] 
1.48 [0.89, 2.46] 
 
KPS * 
    ≤80  
    81 – 90 
    91 - 100 
 
33 (29) 
33 (25) 
23 (18) 
 
12.0 [5.25, 18.75] 
12.0 [10.75, 13.25] 
15.0 [13.45, 16.55] 
0.429  
1 
0.82 [0.48, 1.39] 
0.69 [0.38, 1.25] 
 
Localisation ** 
    Frontal 
    Non-frontal 
    Diffuse+ 
 
25 (19) 
61 (49) 
6   (6) 
 
13.0 [1.58, 24.42] 
13.0 [11.09, 14.91] 
4.0   [0.00, 8.80] 
0.003  
1 
1.03 [0.60, 1.75] 
4.07 [1.57, 10.59] 
 
Resection *** 
    Partial 
    Complete  
 
53 (44) 
39 (29) 
 
11.0  [6.54, 15.46] 
14.0  [11.38, 16.62] 
0.041  
1 
0.62 [0.39, 0.99] 
 
MGMT 
    Methylated 
    Unmethylated  
 
49 (37) 
49 (43) 
 
13.0  [9.08, 16.92] 
12.0  [10.05, 13.95] 
0.171  
1 
1.35 [0.87, 2.11] 
 
Treatment **** 
   Ɨ  RT + TMZ full 
   ¥ RT + TMZ partial 
   RT alone 
   Palliative 
 
39 (24) 
24 (24) 
4   (4) 
11 (10) 
 
24.0 [4.64, 43.36] 
9.0   [7.21, 10.79] 
1.0   [----] 
2.0   [----] 
<0.001  
1 
3.89   [2.12, 7.13] 
24.43 [7.24, 82.40] 
7.13   [3.31, 15.38] 
 
PPARα IHC 
    High 
    Low  
 
 
60 (46) 
40 (35) 
 
12.0 [9.13, 14,87] 
12.0 [9.05, 14.95] 
0.596  
1 
0.89 [0.57, 1.39] 
Table 3:  Overall survival vs. clinical covariates and PPARα IHC expression (n=100) 
In this cohort (n=100), the median overall survival (OS) for all patients was 10 months (range: 1 – 58 
months).  The OS for all patients was 53% at 1 year, 26% at 2 years and 21% at 3 years.  Patients 
who had undergone a partial resection or biopsy only were more likely to receive no adjuvant 
therapy (Pearson Chi-squared test: p=0.022).  Under a Holm-Bonferroni correction for multiplicity of 
tests the above significant effects remain statistically significant except for ‘Resection’.  KPS, 
Karnofsky Performance Score; RT, radiotherapy; TMZ, temozolomide.  The bold denotes statistical 
significance. 
+   Includes multifocal and thalamic tumours 
Ɨ  Includes full 60Gy (30) plus concurrent TMZ with full 6 cycles adjuvant TMZ 
¥ Includes full 60Gy (30) plus concurrent TMZ without full 6 cycles adjuvant TMZ   OR 
Includes full 60Gy (30) without concurrent TMZ but with full 6 cycles adjuvant TMZ 
 
* 11 missing data points 
** 8 missing data points 
*** 8 missing data points 
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**** 22 missing data points 
 
Clinicopathological variable Patients 
(n=473) 
PPARA high PPARA low p-value 
Age (years)    0.626** 
≤55 161 85 76  
56-64 140 72 68  
≥65 172 82 90  
MGMT promoter methylation *    0.063 
Methylated 141 69 72  
Unmethylated 164 62 102  
 
Table 4:  Association between PPARA mRNA expression and clinicopathological features of 
IDH1-wildtype glioblastoma. 
Recurrent tumours and IDH-mutant tumours were excluded from this TCGA data set analysis.  The 
test statistic is Fisher’s exact test; 2 tailed p value.  No significant associations as reported.   
* 168 missing data points 
** The test statistic is Freeman-Halton extension of the Fisher exact probability test 
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Factor n 
 
Median OS 
(months) 
[95% CI] 
p-value 
(log-
rank) 
Hazard Ratio 
[95% CI] 
     
Age 
   11 – 55 
   56 – 65 
   66 – 83  
 
161 
140 
172 
 
14.7  [12.96, 16.49] 
12.9  [10.91, 14.98] 
7.5    [5.50, 9.50] 
<0.001  
1 
1.36 [1.08, 1.72] 
2.27 [1.82, 2.85] 
 
MGMT * 
    Methylated 
    Unmethylated  
 
141 
164 
 
12.2  [9.72, 14.68] 
10.2  [8.75, 11.65] 
0.003  
1 
1.42 [1.13, 1.79] 
 
Treatment ** 
  Ɨ RT + TMZ full 
 ¥ RT + TMZ partial 
   RT alone 
   Palliative 
 
193 
118 
135 
10 
 
13.8 [12.64, 14.96] 
14.9 [13.18, 16.62] 
5.4   [3.96, 6.84] 
3.6   [1.43, 5.77] 
<0.001  
1 
0.74   [0.59, 0.94] 
2.16   [1.73, 2.70] 
3.70   [1.95, 7.03] 
 
 
Table 5:  Overall survival vs. clinical covariates in the TCGA data set (n=473) 
 
Recurrent tumours and IDH-mutant tumours were excluded from this TCGA data set analysis. In 
this data set, the median overall survival (OS) for all patients was 14.9 months from the date of 
diagnosis (range: 0.1 – 127.6 months).  The OS for all patients was 48.4% at 1 year, 15.6% at 2 
years and 7.0% at 3 years.  Patient age, MGMT methylation status and adjuvant treatment modality 
were available covariates in the TCGA data.  Death occurred in all patients in this data set.  Under a 
Holm-Bonferroni correction for multiplicity of tests the above significant effects remain statistically 
significant.  RT, radiotherapy; TMZ, temozolomide.   The bold denotes statistical significance. 
 
Ɨ  Includes full 60Gy (30) plus concurrent TMZ with full 6 cycles adjuvant TMZ 
¥ Includes full 60Gy (30) plus concurrent TMZ without full 6 cycles adjuvant TMZ   OR 
Includes full 60Gy (30) without concurrent TMZ but with full 6 cycles adjuvant TMZ 
 
* 168 missing data points 
** 17 missing data points  
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Factor 
a
 
p-value 
 
Overall survival 
Hazard Ratio 
[95% CI] 
Factor 
b
 
p-value  Overall survival 
Hazard Ratio 
[95% CI] 
PPARA 
 
0.067 0.58 
[0.32, 1.04] 
PPARA 
 
0.042 0.55 
[0.31, 0.98] 
Age 
    
<0.001 1.02 
[1.01, 1.03] 
Age 
    
<0.001 1.02 
[1.01 - 1.03] 
MGMT  
Methylated 
Unmethylated     
0.041 
 
 
1 
1.32 [1.01, 1.73] 
MGMT  
Methylated 
Unmethylated 
     
0.002 
 
 
 
1 
1.05 [1.15 – 1.88] 
Treatment * 
  Ɨ RT + TMZ full 
 ¥ RT + TMZ partial 
   RT alone 
   Palliative 
<0.001 
 
 
 
 
1 
0.77  [0.61, 0.97] 
2.02  [1.61, 2.55] 
3.01  [1.57, 5.79] 
 
Treatment * 
  Ɨ RT + TMZ full 
 ¥ RT + TMZ partial 
   RT alone 
   Palliative 
<0.001 
 
 
 
 
1 
0.81 [0.64 – 1.02] 
2.04 [1.63 – 2.58] 
2.99 [1.54 – 5.78] 
 
Table 6:  Multivariate analysis of factors associated with overall survival in the TCGA data 
set (n=473a; n=472b) 
Recurrent tumours and IDH-mutant tumours were excluded from this TCGA data set analysis.  
Multiple imputation was performed 1000 times for 168 missing MGMT values before multivariate 
analysis. (a) model with single OS outlier included.  (b) model with single OS outlier excluded.  
PPARA mRNA values and age are expressed as continuous variables.  RT, radiotherapy; TMZ, 
temozolomide.   The bold denotes statistical significance. 
 
Ɨ Includes full 60Gy (30) plus concurrent TMZ with full 6 cycles adjuvant TMZ 
¥ Includes full 60Gy (30) plus concurrent TMZ without full 6 cycles adjuvant TMZ   OR 
Includes full 60Gy (30) without concurrent TMZ but with full 6 cycles adjuvant TMZ 
 
 * 17 missing data points  
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Table 7:  Correlation between PPARA and selected differentially expressed gene mRNA 
values in paired samples in the TCGA (n=487) and Rembrandt (n=217) data sets. 
The test statistic is Pearson's product moment correlation.  All correlations have a p-value <0.001. 
  
PPARA vs gene TCGA dataset, Pearson’s r (95% CI) Rembrant dataset, Pearson’s r (95% CI) 
EGFR 0.24   (0.15-0.32) 0.37   (0.25-0.48) 
EMX2 0.28   (0.20-0.36) 0.28   (0.15-0.40) 
AQP4 0.27   (0.19-0.35) 0.34   (0.21-0.45) 
NPAS3 0.35   (0.27-0.42) 0.21   (0.08-0.33) 
NTRK2 0.30   (0.21-0.38) 0.30   (0.21-0.38) 
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